"Boldness be my friend" (Shakespeare; Cymbeline)

Jessica K. Altman*, Martin S. Tallman

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

2 Scopus citations


Au et al. report in this issue of Blood that oral arsenic trioxide (ATO) may be safely used in maintenance therapy in acute promyelocytic leukemia (APL).1 This is a major improvement in convenience given that intravenous (IV) ATO requires daily administration for weeks at a time. In addition, the oral formulation may be less toxic. The time seems right to carefully explore the introduction of oral ATO earlier in treatment of the disease.

Original languageEnglish (US)
Pages (from-to)6477-6478
Number of pages2
Issue number25
StatePublished - Dec 15 2011

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology


Dive into the research topics of '"Boldness be my friend" (Shakespeare; Cymbeline)'. Together they form a unique fingerprint.

Cite this